Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome

Recruiting

• Conditions: Hepatopulmonary Syndrome (HPS)
• Interventions: Biological: Proteomic sequencing

• Registration Number: NCT05932927
• Lead Sponsor: Sun Jie

Brief Summary

Hepatopulmonary syndrome (HPS) has unknown pathogenesis, limited treatment and poor prognosis. The onset of HPS is insidious and easy to be ignored. Many liver diseases such as "cirrhosis and related complications" are the core characteristics of Beijing You 'an Hospital, but the clinical characteristics of HPS patients in the center are still unclear. The investigators plan to make the diagnosis of HPS among chronic liver disease patients in the hospital according to the diagnostic criteria of HPS proposed in the Practice Guidelines of the International Society of Liver Transplantation in 2016, collect clinical data of HPS participants, evaluate the severity, analyze and summarize clinical characteristics, and conduct management and follow-up. At the same time, The investigators collect blood samples for proteomics tests. In order to improve the diagnosis and treatment level of HPS.

Detailed Description

At present, the mechanism of hepatopulmonary syndrome is not clear. The researchers plan to use the extracted plasma for detection, protein extraction and quality control, and then proteolytic hydrolysis, computer detection, and bioinformatics analysis.

Study Timeline

• Study Start: 2023-04-01
• Study First Submitted: 2023-06-09
• Status Verified: 2023-07
• Study First Submitted QC: 2023-07-03
• Last Update Submitted: 2023-07-03
• Study First Posted: 2023-07-06
• Last Update Posted: 2023-07-06
• Primary Completion: 2024-04-01
• Study Completion: 2024-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• chronic hepatitis Agreed to venous blood collection

Exclusion Criteria

• pneumonia, pulmonary vascular disease, interstitial pulmonary disease, COPD, bronchial asthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinal bleeding.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic liver disease with hepatopulmonary syndrome	Proteomic sequencing	Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (\>20 mm Hg if age \> 64)
Chronic liver disease without hepatopulmonary syndrome	Proteomic sequencing	Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE

Primary Outcome Measures

Name	Time	Method
Proteomic results of participants	April 1,2024	Qualitative and quantitative analysis of proteome

Trial Locations

Locations (1)

No.8, Xitoutiao, Youan Men Wai, Fengtai District; 🇨🇳 Beijing, China